PT -期刊文章AU -哈维,艾琳·s . AU -兰顿,大卫AU - Katelaris,康斯坦斯盟-史蒂文斯,肖恩AU -法拉,克劳德·s . AU -吉尔曼,Andrew AU -哈灵顿,约翰AU -凿,马克AU -科里提科斯,Vicky盟——Radhakrishna Naghmeh盟——Bardin菲利普AU -彼得斯,马修AU -雷诺兹,保罗•n . AU - Upham John w . AU - Baraket梅丽莎盟——圆顶礼帽,西蒙AU -鲍登,Jeffrey盟——狗,Jimmy AU - Chung,李平盟——Grainge鳌,Katsoulotos Christopher AU -詹金斯格雷戈里。非盟-李,欢乐盟——麦当劳,凡妮莎·m . AU - Reddel海伦k . AU -轮辋,珍妮特盟-沃克,彼得A.B. AU -吉布森,Peter g . TI - Mepolizumab有效性和识别super-responders严重哮喘援助- 10.1183/13993003.02420 -2019 DP - 2020年5月01 TA -欧洲呼吸杂志》第六PG - 1902420 - 55 IP - 5 4099 - //www.qdcxjkg.com/content/55/5/1902420.short 4100 - //www.qdcxjkg.com/content/55/5/1902420.full所以欧元和J2020可能01;55ab -严重哮喘是一种高负担疾病。需要mepolizumab在严重嗜酸性粒细胞性哮喘患者中的真实数据，以评估随机对照试验的数据是否适用于更广泛的人群。澳大利亚Mepolizumab注册(AMR)旨在评估Mepolizumab在澳大利亚治疗严重嗜酸性粒细胞性哮喘的使用、有效性和安全性。重度嗜酸性粒细胞性哮喘患者(n=309)(中位年龄60岁，58%女性)开始mepolizumab治疗。他们的症状控制较差(哮喘控制问卷(ACQ)-5中位数得分为3.4)，频繁发作(在过去12个月中位数口服皮质类固醇(OCS) 3个疗程)，47%的患者每天需要OCS。中位基线外周血嗜酸性粒细胞水平为590细胞·µL−1。共病很常见:变应性鼻炎63%，胃食管反流病52%，肥胖46%，鼻息肉34%。与前一年相比，Mepolizumab治疗减少了需要OCS的加重(年化率比0.34 (95% CI 0.29-0.41);p<0.001)和住院(比率为0.46(95%可信区间0.33-0.63);术中,0.001)。 Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6 months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index ≥30 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline.Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.In clinical practice, mepolizumab reduces the burden of severe eosinophilic asthma by reducing severe exacerbations and improving asthma control, quality of life and lung function. Super-responders have a T2 phenotype and few comorbidities. http://bit.ly/2UIio4x